Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
JERSEY, Channel Islands, April 10, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the closing of its underwritten public offering of 8,050,000 of its ordinary shares at a price to the public of $6.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional ordinary shares. The offering generated gross proceeds of approximately $48.3 million with Quotient receiving net proceeds of approximately $45.1 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Quotient.
Jefferies LLC acted as sole book-running manager and BTIG, LLC acted as the lead manager for the offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The securities described above were offered by Quotient pursuant to a shelf registration statement on Form S-3 that was filed by Quotient with the Securities and Exchange Commission (SEC) and declared effective on August 17, 2015. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388 or by email at [email protected]; and BTIG, LLC, Equity Capital Markets, 825 Third Avenue, New York, NY 10022, or by telephone at (212) 593-7555 or by email at [email protected].
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Christopher Lindop, Chief Financial Officer — [email protected]; +41 22-545-5226
